These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

943 related articles for article (PubMed ID: 33541771)

  • 21. Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS).
    Kamitaki BK; Minacapelli CD; Zhang P; Wachuku C; Gupta K; Catalano C; Rustgi V
    Epilepsy Behav; 2021 Apr; 117():107832. PubMed ID: 33626490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research.
    Franco V; Bialer M; Perucca E
    Neuropharmacology; 2021 Mar; 185():108442. PubMed ID: 33347884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome.
    Besag FMC; Vasey MJ; Chin RFM
    Expert Opin Pharmacother; 2023; 24(11):1249-1268. PubMed ID: 37212330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazam.
    Rana RR; Rajasekaran K; Knappertz V; Gray RA
    Exp Neurol; 2023 Feb; 360():114286. PubMed ID: 36442674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.
    Morrison G; Crockett J; Blakey G; Sommerville K
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1009-1031. PubMed ID: 30791225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
    Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ
    Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabidiol (Epidiolex) for epilepsy.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):182-184. PubMed ID: 30681657
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.
    Sills GJ
    Ther Adv Neurol Disord; 2023; 16():17562864231191000. PubMed ID: 37655228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
    Devinsky O; Thiele EA; Wright S; Checketts D; Morrison G; Dunayevich E; Knappertz V
    Acta Neurol Scand; 2020 Dec; 142(6):531-540. PubMed ID: 32592183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Commentary on: Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.
    Czuczwar SJ
    Epilepsia; 2020 Oct; 61(10):2063-2064. PubMed ID: 33460074
    [No Abstract]   [Full Text] [Related]  

  • 34. Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program.
    Gaston TE; Bebin EM; Cutter GR; Grayson L; Szaflarski JP
    Epilepsia Open; 2023 Dec; 8(4):1405-1412. PubMed ID: 37593907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Antiseizure Medications on Appetite and Weight in Children.
    Buraniqi E; Dabaja H; Wirrell EC
    Paediatr Drugs; 2022 Jul; 24(4):335-363. PubMed ID: 35596110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
    Strzelczyk A; Schubert-Bast S
    CNS Drugs; 2022 Mar; 36(3):217-237. PubMed ID: 35156171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.
    Anderson LL; Absalom NL; Abelev SV; Low IK; Doohan PT; Martin LJ; Chebib M; McGregor IS; Arnold JC
    Epilepsia; 2019 Nov; 60(11):2224-2234. PubMed ID: 31625159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiseizure Medication-Induced Alopecia: A Literature Review.
    Pitton Rissardo J; Fornari Caprara AL; Casares M; Skinner HJ; Hamid U
    Medicines (Basel); 2023 Jun; 10(6):. PubMed ID: 37367730
    [No Abstract]   [Full Text] [Related]  

  • 39. A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?
    Cross JH; Cock H
    Neuropharmacology; 2020 Jun; 170():107861. PubMed ID: 31770546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
    Devinsky O; Patel AD; Thiele EA; Wong MH; Appleton R; Harden CL; Greenwood S; Morrison G; Sommerville K;
    Neurology; 2018 Apr; 90(14):e1204-e1211. PubMed ID: 29540584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.